Follow Medpace Holdings to never miss an important update.
Medpace will share its latest quarterly results in about nine days. Analysts expect revenue of about 710 million dollars, and the company has a long track record of beating those estimates. For a long-term owner, the most important numbers to watch are the new business awards and the backlog. These show how much work the company has signed for the future, which is the best way to tell if its focus on small biotech firms is still winning against larger rivals.
Mizuho Securities raised its price target for the company from $665 to $700 on Wednesday. This move places their target well above the average analyst estimate of $620. While a target change on its own is routine, it reflects continued confidence in the company's ability to win business from small biotech firms. These smaller clients rely heavily on outside help to run drug trials, which has historically allowed the company to earn higher profits than rivals who focus on large pharmaceutical giants.
Source: Mizuho Securities
UBS analysts raised their rating on the stock from sell to neutral, signaling they no longer see the company as likely to underperform. The firm also set a price target of $673, which is about 9 percent higher than the current stock price.
This change is notable because Medpace relies on smaller biotech companies that are sensitive to interest rates and funding cycles. A move to a neutral rating suggests analysts are becoming more comfortable with how the company is managing through the current environment for its customers.
Source: UBS
BMO Capital raised its price target by 50 percent, moving it from $400 to $600. The firm maintained its neutral rating, which suggests they see the business performing well but believe the stock is now priced fairly.
The sharp increase reflects a rebound in the company's bookings, which are the new contracts signed for future work. After a slower start to the year, this surge in new business helps secure the company's revenue path for the coming quarters.
Source: BMO Capital
RBC Capital significantly increased its price target for the stock from $484 to $692 while keeping a positive rating. This move comes after the company reported better-than-expected results for the second quarter.
This large adjustment suggests analysts have much higher confidence in the company's ability to win new business from small biotech firms. When analysts raise targets this sharply, it usually means they believe the company's specialized model is more resilient to market swings than they previously thought.
Source: RBC Capital
Management has a perfect record of beating their own targets for two years straight. This suggests they are masters of setting a bar they know they can clear.
| Expectation | |
|---|---|
| EPS | $4.44 |
| Revenue | $714M |
Follow Medpace Holdings to get the latest and most important updates.
Follow MEDP